Probiotics and Nonalcoholic Fatty liver Disease

Tannaz Eslamparast, Sareh Eghtesad, Azita Hekmatdoost, Hossein Poustchi, Tannaz Eslamparast, Sareh Eghtesad, Azita Hekmatdoost, Hossein Poustchi

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common chronicliver disease worldwide, both in adults and in children. NAFLD represents aspectrum of liver diseases that range from hepatic steatosis to steatohepatitisand cirrhosis. However, NAFLD is more prevalent in overweight and obeseindividuals. Evidences thus far suggest that hepatic triglyceride accumulationis not always derived from obesity; gut microbiota can also play a role in thedevelopment of insulin resistance, hepatic steatosis, necroinflammation andfibrosis. On the other hand, probiotics can strengthen the intestinal wall, reducingits permeability, bacterial translocation, and endotoxemia according toanimal and human studies. They can also reduce oxidative and inflammatoryliver damage, while improving the histological state in certain situations. Thisreview article focuses on research that has been conducted on probiotics andNAFLD, highlighting their efficacy as a novel therapeutic option for the treatmentof this condition.

Keywords: Nonalcoholic fatty liver; Probiotics; cirrhosis.

References

    1. Björnsson E. The clinical aspects of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2008;54:7–18.
    1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.
    1. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander- Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.
    1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–609.
    1. Day C. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002;16:663–78.
    1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112.
    1. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40 Suppl 1:S17–29.
    1. Duvnjak M, Lerotić I, Barsić N, Tomasić V, Virović Jukić L, Velagić V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol. 2007;13:4539–50.
    1. Kojima H, Sakurai S, Uemura M, Fukui H, Morimoto H, Tamagawa Y. Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis. Alcohol Clin Exp Res. 2007;31:S61–6.
    1. Solga SF, Diehl A. Non-alcoholic fatty liver disease: lumen–liver interactions and possible role for probiotics. J Hepatol. 2003;38:681–7.
    1. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2010;103:71–83.
    1. Hickman I, Jonsson J, Prins J, Ash S, Purdie D, Clouston A. et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004;53:413–9.
    1. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J. et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2005;100:1072–81.
    1. Masterton G, Plevris J, Hayes P. Review article: omega-3 fatty acids–a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2010;31:679–92.
    1. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:2485–90.
    1. Merat S, Malekzadeh R, Sohrabi MR, Sotoudeh M, Rakhshani N, Sohrabpour AA. et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol. 2003;38:414–8.
    1. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P. et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39:770–8.
    1. Emel Pamuk G, Sonsuz A. N-Acetylcysteine in The Treatment Of Non-Alcoholic Steatohepatitis. J Gastroenterol Hepatol. 2003;18:1220–1.
    1. Fassio E, Álvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies. Hepatology. 2004;40:820–6.
    1. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42:132–8.
    1. Farrell G. Is bacterial ash the flash that ignites NASH? Gut. 2001;48:148–9.
    1. Loguercio C, De Simone T, Federico A, Terracciano F, Tuccillo C, Di Chicco M. et al. Gut-liver axis: a new point of attack to treat chronic liver damage? Am J Gastroenterol. 2002;97:2144–6.
    1. Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem. 2011;22:699–711.
    1. Zeuzem S. Gut-liver axis. Int J Colorectal Dis. 2000;15:59–82.
    1. Laflamme N, Rivest S. Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components. FASEB J. 2001;15:155–63.
    1. Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun. 1979;23:403–11.
    1. Jacob A, Goldberg P, Bloom N, Degenshein G, Kozinn P. Endotoxin and bacteria in portal blood. Gastroenterology. 1977;72:1268.
    1. Nolan JP. Endotoxin, reticuloendothelial function, and liver injury. Hepatology. 1981;1:458–65.
    1. Mathison JC, Ulevitch RJ. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol. 1979;123:2133–43.
    1. Ruiter D, Van der Meulen J, Brouwer A, Hummel M, Mauw B, Van der Ploeg J. et al. Uptake by liver cells of endotoxin following its intravenous injection. Lab Invest. 1981;45:38–45.
    1. Jirillo E, Caccavo D, Magrone T, Piccigallo E, Amati L, Lembo A. et al. Review: The role of the liver in the response to LPS: experimental and clinical findings. J Endotoxin Res. 2002;8:319–27.
    1. Compare D, Coccoli P, Rocco A, Nardone O, De Maria S, Cartenì M. et al. Gut–liver axis: The impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2012;22:471–6.
    1. Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics—approaching a definition. Am J Clin Nutr. 2001;73:361S–4S.
    1. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr. 1999;135:564–8.
    1. Cesaro C, Tiso A, Del Prete A, Cariello R, Tuccillo C, Cotticelli G. et al. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis. 2011;43:431–8.
    1. Frazier TH, DiBaise JK, McClain CJ. Gut Microbiota, Intestinal Permeability, Obesity-Induced Inflammation, and Liver Injury. JPEN J Parenter Enteral Nutr. 2011;35:14S–20S.
    1. Hakansson A, Molin G. Gut microbiota and inflammation. Nutrients. 2011;3:637–82.
    1. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology. 2006;43:S54–S62.
    1. Su GL. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am J Physiol Gastrointest Liver Physiol. 2002;283:G256–65.
    1. Tobias PS, Soldau K, Gegner JA, Mintz D, Ulevitch RJ. Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J Biol Chem. 1995;270:10482–8.
    1. Baldwin Jr AS. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–83.
    1. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C. et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121:580–91.
    1. Resta-Lenert S, Barrett K. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC) Gut. 2003;52:988–97.
    1. Ghosh S, Van Heel D, Playford R. Probiotics in inflammatory bowel disease: is it all gut flora modulation? Gut. 2004;53:620–2.
    1. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB. et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37:343–50.
    1. Haller D, Bode C, Hammes W, Pfeifer A, Schiffrin E, Blum S. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut. 2000;47:79–87.
    1. Grönlund M, Arvilommi H, Kero P, Lehtonen O, Isolauri E. Importance of intestinal colonisation in the maturation of humoral immunity in early infancy: a prospective follow up study of healthy infants aged 0–6 months. Arch Dis Child Fetal Neonatal Ed. 2000;83:F186–92.
    1. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N. et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002;35:367–72.
    1. Farrell GC. Signalling links in the liver: knitting SOCS with fat and inflammation. J Hepatol. 2005;43:193–6.
    1. Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palù G. et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2007;292:G518–25.
    1. Kim JJ, Sears DD. TLR4 and insulin resistance. Gastroenterol Res Pract. 2010
    1. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.
    1. Creely SJ, McTernan PG, Kusminski CM, Da Silva N, Khanolkar M, Evans M. et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292:E740–7.
    1. Peraldi P, Spiegelman B. TNF-α and insulin resistance: summary and future prospects. Mol Cell Biochem. 1998;182:169–75.
    1. Al-Salami H, Butt G, Fawcett JP, Tucker IG, Golocorbin- Kon S, Mikov M. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. Eur J Drug Metab Pharmacokinet. 2008;33:101–6.
    1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–18.
    1. Seki E, De Minicis S, Österreicher CH, Kluwe J, Osawa Y, Brenner DA. et al. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat Med. 2007;13:1324–32.
    1. Brun P, Castagliuolo I, Pinzani M, Palù G, Martines D. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2005;289:G571–8.
    1. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology. 2003;37:1043–55.
    1. Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol. 2008;49:821–30.
    1. Nardone G, Compare D, Liguori E, Di Mauro V, Rocco A, Barone M. et al. Protective effects of Lactobacillus paracasei F19 in a rat model of oxidative and metabolic hepatic injury. Am J Physiol Gastrointest Liver Physiol. 2010;299:G669–76.
    1. Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P. et al. Probiotics Reduce the Inflammatory Response Induced by a High-Fat Diet in the Liver of Young Rats. J Nutr. 2009;139:905–11.
    1. Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P. et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology. 2009;49:989–97.
    1. Mencarelli A, Distrutti E, Renga B, D’Amore C, Cipriani S, Palladino G. et al. Probiotics Modulate Intestinal Expression of Nuclear Receptor and Provide Counter-Regulatory Signals to Inflammation-Driven Adipose Tissue Activation. PLoS One. 2011;6:e22978.
    1. Xu R, Wan Y, Fang Q, Lu W, Cai W. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J Clin Biochem Nutr. 2012;50:72–7.
    1. Wang Y, Xu N, Xi A, Ahmed Z, Zhang B, Bai X. Effects of Lactobacillus plantarum MA2 isolated from Tibet kefir on lipid metabolism and intestinal microflora of rats fed on high-cholesterol diet. Appl Microbiol Biotechnol. 2009;84:341–7.
    1. Lee H-Y, Park J-H, Seok S-H, Baek M-W, Kim D-J, Lee K-E. et al. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta. 2006;1761:736–44.
    1. Yadav H, Jain S, Sinha PR. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition. 2007;23:62–8.
    1. Million M, Angelakis E, Paul M, Armougom F, Leibovici L, Raoult D. Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. Microb Pathog. 2012;53:100–8.
    1. Loguercio C, Federico A, Tuccillo C, Terracciano F, D’Auria MV, De Simone C. et al. Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases. J Clin Gastroenterol. 2005;39:540–3.
    1. Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S. et al. Effects of Lactobacillus rhamnosus Strain GG in Pediatric Obesity-related Liver Disease. J Pediatr Gastroenterol Nutr. 2011;52:740–3.
    1. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D. et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011;15:1090–5.
    1. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R. et al. Bifidobacterium longum with Fructo-Oligosaccharides in Patients with Non Alcoholic Steatohepatitis. Dig Dis Sci. 2012;57:545–53.
    1. Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev. 2007;1:CD005165.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다